Based on these observations, we concluded that the combined treatment with JNJ-165 and a TKI might offer a novel therapeutic strategy not only for p53 wild-type CML patients, but also for the patients with p53 mutation that is detected in about 20% of patients in blast crisis [15, 16]. Here, TP53 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.